FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA [MarketWatch]
Last abbvie, inc earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA The U.S. Food and Drug Administration has approved AbbVie Inc's ABBV, +2.10% Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn't worked, AbbVie announced Friday. The pharmaceutical company said Rinvoq should be available in the U.S. later this month. "Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity - the primary treatment goals for rheumatoid arthritis," said Roy Fleischmann, a clinical professor at the University of Texas Southwestern Medical Center at Dallas who led one of AbbVie's clinical trials of Rinvoq. "With this FDA approval, Rinvoq has the potential to help additional people living with RA achieve remission who have not yet reached this goal." The European Medicines Agency and regulatory authorities in Canada and Japan are still
[Read more]
| Impact snapshot | Event time: | ABBV | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ABBV alerts
ABBV alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie, Inc news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Truist. They set a "buy" rating and a $110.00 price target on the stock.MarketBeat
- AbbVie Inc. (NYSE: ABBV) was downgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "sell" rating.MarketBeat
- AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic DermatitisPR Newswire
- AbbVie Announces Commencement of Registered Exchange OffersPR Newswire
- VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)PR Newswire
- More
ABBV
SEC Filings
- 10/19/20 - Form 8-K
- 10/19/20 - Form 424B3
- 10/19/20 - Form EFFECT
- ABBV's page on the SEC website
- More